Achieve Life Sciences, Inc.
ACHV
$-0.10
Change (1 day)
$5.98
Year High
$3.03
Year Low
Categories
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
P/E ratio for Achieve Life Sciences, Inc. (ACHV)
P/E ratio as of 2023: -2.74
According to Achieve Life Sciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.74. At the end of 2022 the company had a P/E ratio of -0.62.
P/E ratio history for Achieve Life Sciences, Inc. from 1994 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.74 |
| 2022 | -0.62 |
| 2021 | -1.92 |
| 2020 | -1.50 |
| 2019 | -0.27 |
| 2018 | -0.33 |
| 2017 | -0.61 |
| 2016 | -0.74 |
| 2015 | -1.88 |
| 2014 | -1.58 |
| 2013 | -3.84 |
| 2012 | -8.41 |
| 2011 | -7.78 |
| 2010 | -9.38 |
| 2009 | 23.07 |
| 2008 | -3.93 |
| 2007 | -1.25 |
| 2006 | -9.55 |
| 2005 | -7.28 |
| 2004 | -4.62 |
| 2003 | -8.71 |
| 2002 | -2.49 |
| 2001 | 173.51 |
| 2000 | -2.79 |
| 1999 | 56.18 |
| 1998 | -5.18 |
| 1997 | 284.65 |
| 1996 | 149.00 |
| 1995 | -17.87 |
| 1994 | -6.52 |